Nurix Therapeutics Inc (NASDAQ:NRIX) — Market Cap & Net Worth
Market Cap & Net Worth: Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ:NRIX) has a market capitalization of $1.93 Billion ($1.93 Billion) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6295 globally and #2006 in its home market, demonstrating a -5.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nurix Therapeutics Inc's stock price $24.83 by its total outstanding shares 101369235 (101.37 Million). Also see Nurix Therapeutics Inc (NRIX) total assets for a full breakdown of the balance sheet.
Nurix Therapeutics Inc Market Cap History: 2020 to 2026
Nurix Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $3.33 Billion to $2.52 Billion (4.44% CAGR). Also see Nurix Therapeutics Inc (NRIX) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Nurix Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.07% | #178 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #715 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.10% | #107 of 263 |
Weight: Nurix Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nurix Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nurix Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Nurix Therapeutics Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
35.01x
Nurix Therapeutics Inc's market cap is 35.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.33 Billion | $17.82 Million | -$43.24 Million | 187.04x | N/A |
| 2021 | $2.93 Billion | $29.75 Million | -$117.19 Million | 98.64x | N/A |
| 2022 | $1.11 Billion | $38.63 Million | -$166.04 Million | 28.81x | N/A |
| 2023 | $1.05 Billion | $76.99 Million | -$143.95 Million | 13.59x | N/A |
| 2024 | $1.91 Billion | $54.55 Million | -$193.57 Million | 35.01x | N/A |
Competitor Companies of NRIX by Market Capitalization
Companies near Nurix Therapeutics Inc in the global market cap rankings as of September 17, 2026. Review how tangible is Nurix Therapeutics Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nurix Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Nurix Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Nurix Therapeutics Inc's market cap moved from $3.33 Billion to $ 2.52 Billion, with a yearly change of 4.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.52 Billion | +30.89% |
| 2025 | $1.92 Billion | +0.69% |
| 2024 | $1.91 Billion | +82.56% |
| 2023 | $1.05 Billion | -6.01% |
| 2022 | $1.11 Billion | -62.07% |
| 2021 | $2.93 Billion | -11.95% |
| 2020 | $3.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Nurix Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.93 Billion USD |
| MoneyControl | $1.93 Billion USD |
| MarketWatch | $1.93 Billion USD |
| marketcap.company | $1.93 Billion USD |
| Reuters | $1.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more